Free Trial

IGM Biosciences (IGMS) Competitors

IGM Biosciences logo
$1.35 -0.01 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.35 0.00 (0.00%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGMS vs. ALLO, INZY, TNXP, LIMN, CADL, PVLA, DBVT, SGMT, IMMP, and ACB

Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Tonix Pharmaceuticals (TNXP), Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.

IGM Biosciences vs. Its Competitors

IGM Biosciences (NASDAQ:IGMS) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

In the previous week, IGM Biosciences had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for IGM Biosciences and 1 mentions for Allogene Therapeutics. IGM Biosciences' average media sentiment score of 0.51 beat Allogene Therapeutics' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IGM Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

IGM Biosciences presently has a consensus price target of $5.50, indicating a potential upside of 307.41%. Allogene Therapeutics has a consensus price target of $8.44, indicating a potential upside of 627.97%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than IGM Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IGM Biosciences
1 Sell rating(s)
9 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.90
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Allogene Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Allogene Therapeutics' return on equity of -52.98% beat IGM Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IGM Biosciences-7,417.79% -317.97% -71.43%
Allogene Therapeutics N/A -52.98%-41.28%

IGM Biosciences has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM Biosciences$2.68M30.11-$195.79M-$3.27-0.41
Allogene Therapeutics$20K12,686.34-$257.59M-$1.23-0.94

Summary

Allogene Therapeutics beats IGM Biosciences on 9 of the 16 factors compared between the two stocks.

Get IGM Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IGMS vs. The Competition

MetricIGM BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$80.70M$2.86B$5.45B$8.93B
Dividend YieldN/A2.44%5.22%4.01%
P/E Ratio-0.4120.4427.2420.06
Price / Sales30.11283.79426.37117.54
Price / CashN/A41.7026.2128.59
Price / Book1.657.397.925.56
Net Income-$195.79M-$55.04M$3.17B$248.56M
7 Day Performance20.54%3.43%4.40%7.56%
1 Month Performance2.27%0.16%2.64%8.54%
1 Year Performance-78.50%4.49%35.04%21.81%

IGM Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IGMS
IGM Biosciences
4.3985 of 5 stars
$1.35
-0.7%
$5.50
+307.4%
-78.4%$80.70M$2.68M-0.41190Positive News
High Trading Volume
ALLO
Allogene Therapeutics
2.9802 of 5 stars
$1.13
-4.2%
$8.44
+647.3%
-43.9%$258.10M$20K-0.92310Gap Down
INZY
Inozyme Pharma
3.3951 of 5 stars
$4.00
+0.3%
$11.75
+193.8%
N/A$257.60MN/A-2.3750Positive News
Analyst Upgrade
TNXP
Tonix Pharmaceuticals
2.5448 of 5 stars
$35.98
+3.1%
$585.00
+1,525.9%
-55.6%$256.69M$10.09M-0.0250
LIMN
Liminatus Pharma
N/A$11.15
+17.6%
N/AN/A$246.62MN/A0.00N/A
CADL
Candel Therapeutics
2.4544 of 5 stars
$5.06
+3.3%
$22.00
+334.8%
-12.4%$245.50M$120K-3.7860
PVLA
Palvella Therapeutics
3.4085 of 5 stars
$22.54
+2.1%
$46.29
+105.3%
N/A$244.11M$42.81M-1.86N/A
DBVT
DBV Technologies
3.7234 of 5 stars
$9.16
+3.2%
$14.75
+61.0%
+175.1%$243.22M$4.15M-1.8680Analyst Upgrade
SGMT
Sagimet Biosciences
2.3807 of 5 stars
$7.62
-3.2%
$26.60
+249.1%
+175.2%$241.41M$2M-4.338
IMMP
Prima BioMed
0.9697 of 5 stars
$1.64
flat
$7.00
+326.8%
-11.9%$239.50M$5.14M0.002,021Positive News
ACB
Aurora Cannabis
0.0903 of 5 stars
$4.24
+2.2%
N/A-5.1%$233.29M$246.72M38.551,130

Related Companies and Tools


This page (NASDAQ:IGMS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners